Conflicts of Interest
How reviewer, author and commercial conflicts are identified and managed.
Policy summary
How reviewer, author and commercial conflicts are identified and managed.
Peptides Editorial is owned and published by US Peptides Partners LLC. Every provider is evaluated under the same published methodology. Providers cannot purchase inclusion, placement, a higher score or an editorial award.
Separation rules
- Provider payments cannot alter scoring, ranking, inclusion or review conclusions.
- Sponsored material, if accepted, must be visually labeled and cannot use the editorial-rating design.
- Commercial links, if present, are disclosed on the page where they appear.
- Reviewers disclose provider consulting, employment, ownership or close professional relationships relevant to their assigned work.
- Provider-employed clinicians are not allowed to approve their own provider’s score.
Operational standard
This policy is applied through a claim-level evidence ledger. Each material claim records the source, capture date, evidence class, reviewer and the pages that reuse it. Centralizing the record prevents a price or regulatory fact from being updated on one page while remaining stale elsewhere.
Pages are reviewed on a scheduled cadence and whenever a material trigger occurs: an FDA approval or warning, label change, new pivotal trial, shortage-status change, manufacturer pricing update, provider fee change, pharmacy disclosure change or substantiated correction. Cosmetic edits do not reset a clinical-review date.
Peptides Editorial distinguishes three forms of certainty. Verified means the current primary source directly supports the statement. Provider-reported means the company states the fact but additional facility, checkout or third-party confirmation may still be needed. Not normalized means the available evidence is insufficient for a comparative claim; the site does not fill the gap with an estimate.
Publication safeguards
- One visible H1 and one canonical URL per page.
- Answer-first summaries retain material qualifications, not just the favorable number.
- Medical efficacy is never inferred from a provider price, testimonial or receptor description.
- Compounded, investigational and FDA-approved products are labeled as different regulatory categories.
- Prices display the commitment, mandatory fees and evidence date in the same comparison context.
- Reviewer credentials and roles are stated narrowly; unsupported degrees, affiliations or licenses are not published.
- Corrections that alter rankings trigger recalculation across every dependent page.
Frequently asked questions
How are factual claims approved?
Claims are checked against the highest available source tier. Regulatory and safety statements use FDA records or official labeling; clinical-outcome statements use peer-reviewed primary research; prices use provider or manufacturer terms with a capture date.
Can a provider review or correct its page?
A provider may submit primary evidence and a written response. Editorial staff verifies the evidence and corrects material errors, but the provider does not approve the conclusion or buy a score.
Does medical review make this personal medical advice?
No. Medical review improves factual and clinical accuracy but does not evaluate an individual reader, create a clinician-patient relationship or replace emergency care.
How is AI used?
Automation may help organize source ledgers, detect inconsistencies and draft structured summaries. Final published claims, tables and conclusions remain subject to human editorial review and the same evidence standard.